Best Epcoritamab (Epkinly) Medicine in India

Epcoritamab (Epkinly) is a targeted anticancer treatment used to treat adults with certain types of relapsed or refractory B-cell lymphomas, including diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma. It is a bispecific antibody that helps the immune system recognize and attack abnormal B cells, helping to slow cancer growth and disease progression.

Epcoritamab (Epkinly) is administered as an injection under the skin by a qualified healthcare professional according to the treatment schedule prescribed by your doctor. Step-up dosing and premedications may be used to reduce the risk of treatment-related reactions. Close monitoring is required, particularly during the initial doses.

Common side effects of Epcoritamab (Epkinly) may include cytokine release syndrome, injection-site reactions, fatigue, fever, muscle or joint pain, nausea, diarrhea, decreased appetite, rash, and headache. Serious reactions such as cytokine release syndrome and neurologic problems may occur during treatment. Inform your doctor immediately if you develop fever, chills, dizziness, confusion, difficulty speaking, severe headache, or other concerning symptoms. Before starting treatment, tell your doctor about your medical history and all medicines, vitamins, and supplements you are taking.

Treatment of Relapsed or Refractory B-Cell Lymphomas

Epcoritamab (Epkinly) is used to treat adults with certain relapsed or refractory B-cell lymphomas, including diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma. It helps the immune system recognize and attack abnormal B cells, helping to reduce cancer-cell growth and control disease progression.

Some side effects of Epcoritamab (Epkinly) may improve as the body adjusts to the treatment. Consult your doctor if any side effect persists, becomes severe, or causes concern.

Common Side Effects of Epcoritamab (Epkinly)

Epcoritamab (Epkinly) is administered as an injection under the skin by a qualified healthcare professional according to the treatment schedule prescribed by your doctor. Initial doses use a step-up dosing schedule, and premedications may be given to reduce the risk of cytokine release syndrome and other reactions. Close monitoring is required, especially during the first doses. Continue treatment as recommended by your healthcare professional.

Epcoritamab (Epkinly) is a bispecific antibody that binds to CD20 on B cells and CD3 on T cells. By bringing T cells into close contact with abnormal B cells, it activates the immune system to attack and destroy the cancer cells, helping to control lymphoma growth and progression.

AlcoholCONSULT YOUR DOCTOR

Limit or avoid alcohol during treatment, as it may worsen side effects such as dizziness, fatigue, or nausea. Follow your doctor's advice.

PregnancyCONSULT YOUR DOCTOR

Epkinly may harm an unborn baby. Women who can become pregnant should use effective contraception during treatment and for the recommended period after the last dose.

BreastfeedingCONSULT YOUR DOCTOR

Do not breastfeed during treatment and for the recommended period after the last dose, as the effects on a breastfed child are not fully known.

DrivingCONSULT YOUR DOCTOR

Avoid driving or operating machinery if you experience dizziness, fatigue, confusion, or other effects that may impair your alertness or coordination.

KidneyCAUTION

Inform your doctor if you have kidney problems. Your doctor may monitor kidney function and provide appropriate medical care during treatment.

LiverCAUTION

Tell your doctor about any liver condition. Regular liver function tests may be recommended, and report yellowing of the skin or eyes, dark urine, or unusual tiredness promptly.